Management of hepatotoxicity associated with CDK4/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-negative breast cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective study assesses hepatotoxicity incidence and rechallenge safety in patients using cdk4/6 inhibitors.

Hepatotoxicity occurred in 10.5% of patients, most frequently associated with younger age and herbal supplement use.
Most patients successfully resumed treatment after dose reduction or switching to another cdk4/6 inhibitor with no severe hepatotoxicity recurrence.
The study included 544 patients treated with ribociclib or palbociclib across multiple oncology centers in Turkey.
Timely management strategies and individualized monitoring enabled safe continuation of therapy in patients post-hepatotoxicity.

İlhan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study assesses hepatotoxicity incidence and rechallenge safety in patients using cdk4/6 inhibitors.

Hepatotoxicity occurred in 10.5% of patients, most frequently associated with younger age and herbal supplement use.
Most patients successfully resumed treatment after dose reduction or switching to another cdk4/6 inhibitor with no severe hepatotoxicity recurrence.
The study included 544 patients treated with ribociclib or palbociclib across multiple oncology centers in Turkey.
Timely management strategies and individualized monitoring enabled safe continuation of therapy in patients post-hepatotoxicity.

İlhan et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark